The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

The clumping of amyloid beta in the brain to form plaques is one the hallmarks of AD, and the 'amyloid hypothesis' suggests they are a primary driver for the neurodegeneration seen in the disease.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

New research offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis. Alzheimer’s disease is a leading cause of death among those aged 65 or older. As the most common ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

Amyloid fibrils appear in many neurodegenerative diseases, and scientists are eager to understand how they form and spread.

An international team led by researchers at the University of Toronto has developed an efficient and robust system, using the C. elegans nematode, to screen for compounds that can stop the growth of ...